Publications by authors named "Jorge Spertino"
Article Synopsis
- - A study evaluated the effectiveness and safety of dupilumab for treating bullous pemphigoid in elderly patients, with a focus on those who typically have other health issues that make standard treatments unsuitable.
- - The results showed that 53.4% of patients achieved complete remission within 4 weeks and 95.7% by week 52, with a significant reduction in itchiness and a dramatic decrease in the need for corticosteroids.
- - The treatment was found to be safe, with most adverse events being mild, and factors like shorter disease duration and exclusive skin involvement were linked to better treatment responses.
Background: Dupilumab has shown to be an effective and safe treatment for patients with moderate-to-severe atopic dermatitis (AD).
Objective: To evaluate the predictive factors of response (PRF) in patients with moderate-to-severe AD treated with dupilumab.
Methods: Observational, retrospective and multicentre study conducted on adult patients diagnosed with moderate-to-severe AD treated with dupilumab, with a post-treatment follow-up of at least 16 weeks.
Article Synopsis
- The study looked at how patients with chronic spontaneous urticaria (CSU) respond to a medicine called omalizumab and whether they still need to take antihistamines (AH).
- Some patients (23.5%) stopped taking AH while on omalizumab and had better results in controlling their symptoms.
- The researchers think more studies are needed to figure out which patients can stop taking antihistamines safely while using omalizumab.